Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain
- PMID: 32248839
- PMCID: PMC7132863
- DOI: 10.1186/s12888-020-02538-8
Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain
Abstract
Background: Real-World Data (RWD) studies provide important insights in disease epidemiology, in real clinical populations, with long follow-up periods. The aim of the present study was to describe the epidemiology of schizophrenia spectrum disorders (SD) during an 8-year period in Spain.
Methods: A retrospective cohort of subjects aged 15 to 64 years was followed-up using electronic healthcare databases of the Valencia region (2008-2015). SD cases included outpatient and inpatient settings (ICD 9 codes 295.XX). Prevalence of SD was assessed. Incidence rate (IR) in the subpopulation aged between 15 and 34 years was also provided. Healthcare utilization (HCU) rates, including outpatient, specialists, hospitalizations and antipsychotic dispensations were estimated.
Results: The cohort included 3,976,071 subjects; 24,749 of them had a prevalent diagnosis of SD. The overall prevalence for SD was 6.2 per 1000 persons. SD were 76% more prevalent in men than women. IR in the subpopulation aged between 15 and 34 years was 50.25 per 100,000 persons years and was more than 2 times higher for men than for women. 83.4% of the overall outpatient visits from the cohort of patients were related to SD. The 21,095 overall hospitalizations with the SD code resulted in 286,139 days of hospitalization, with a median of 4 days (IQR: 1.6-9.2) per person-year. 93.2% of subjects diagnosed with SD were ever treated with some antipsychotic drug during the study period, and 70% of the patients were ever treated with antipsychotic polypharmacy.
Conclusions: This large population-based study using RWD provides novel and recent information SD in a southern European country. The prevalence and IR of SD showed is greater than previously published and higher in men than in women. The fact of having used a large arsenal of electronic data (including outpatient and inpatient) for 8 years may have influenced. SD represents high burden and healthcare utilization. Contrary to guidelines recommendations the majority of patients were ever treated with antipsychotic polypharmacy.
Keywords: Antipsychotics; Epidemiolgy; Incidence; Prevalence; Real world data; Schizophrenia.
Conflict of interest statement
FISABIO has received research grants from various pharmaceutical companies. AOS, MLL, CMQ and JDD ever received travel grants to attend meetings sponsored by pharmaceutical companies. AOS, MLL, CMQ and JDD have been principal investigators in projects sponsored by pharmaceutical companies. JDD acted as Advisor for GSK and SPMSD.
Figures
Similar articles
-
Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014.Psychiatr Serv. 2018 Sep 1;69(9):1015-1020. doi: 10.1176/appi.ps.201800052. Epub 2018 Jul 2. Psychiatr Serv. 2018. PMID: 29962308
-
Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.Clin Ther. 2007 Jan;29(1):183-95. doi: 10.1016/j.clinthera.2007.01.002. Clin Ther. 2007. PMID: 17379060
-
Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.Appl Health Econ Health Policy. 2008;6(1):41-53. doi: 10.2165/00148365-200806010-00004. Appl Health Econ Health Policy. 2008. PMID: 18774869
-
Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data.Curr Med Res Opin. 2019 Jul;35(7):1231-1239. doi: 10.1080/03007995.2019.1571295. Epub 2019 Jan 31. Curr Med Res Opin. 2019. PMID: 30649965
-
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5. Encephale. 2005. PMID: 15959450 Review. French.
Cited by
-
Impact of Cognitive Disturbances and Clinical Symptoms on Disability in Patients with Paranoid Schizophrenia: A Study of a Bulgarian Clinical Sample.Int J Environ Res Public Health. 2023 Jan 30;20(3):2459. doi: 10.3390/ijerph20032459. Int J Environ Res Public Health. 2023. PMID: 36767826 Free PMC article.
-
Stratification by Sex and Hormone Level When Contrasting Men and Women in Schizophrenia Trials Will Improve Personalized Treatment.J Pers Med. 2021 Sep 18;11(9):929. doi: 10.3390/jpm11090929. J Pers Med. 2021. PMID: 34575706 Free PMC article. Review.
-
Into a Deeper Understanding of CYP2D6's Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders.Int J Mol Sci. 2024 Jun 8;25(12):6350. doi: 10.3390/ijms25126350. Int J Mol Sci. 2024. PMID: 38928058 Free PMC article.
-
Molecular mechanisms involved in the prevention and reversal of ketamine-induced schizophrenia-like behavior by rutin: the role of glutamic acid decarboxylase isoform-67, cholinergic, Nox-2-oxidative stress pathways in mice.Mol Biol Rep. 2021 Mar;48(3):2335-2350. doi: 10.1007/s11033-021-06264-6. Epub 2021 Apr 3. Mol Biol Rep. 2021. PMID: 33811574
-
Utilization of psychotropic medicines in Romania during 1998-2018.Front Pharmacol. 2023 Mar 27;14:1157231. doi: 10.3389/fphar.2023.1157231. eCollection 2023. Front Pharmacol. 2023. PMID: 37050903 Free PMC article.
References
-
- Baser O, Xie L, Pesa J, Durkin M. Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J Med Econ. 2015;18(5):357–365. doi: 10.3111/13696998.2014.1001514. - DOI - PubMed
-
- Schizophrenia . WHOMh. WHO. 2018.
-
- Keskinen E, Marttila A, Marttila R, Jones PB, Murray GK, Moilanen K, et al. Interaction between parental psychosis and early motor development and the risk of schizophrenia in a general population birth cohort. Eur Psychiatry. 2015;30(6):719–727. doi: 10.1016/j.eurpsy.2015.04.006. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical